Standard Bio-Tech

Standard BioTools Inc. (Nasdaq: LAB) is a leading provider of high-plex analytical technologies for proteomics, genomics, and spatial biology, headquartered in South San Francisco. Formerly known as Fluidigm Corporation, the company underwent a strategic rebranding in 2022 and significantly expanded its portfolio through a merger with SomaLogic in early 2024. Its flagship systems include the CyTOF® mass cytometry platform for deep immune profiling and the SomaScan® assay, which enables the measurement of over 11,000 proteins from a single sample. These tools are used extensively in translational and clinical research, particularly in oncology and immunology, to identify biomarkers and accelerate drug development. Standard BioTools serves a global network of academic, pharmaceutical, and clinical laboratories with a focus on delivering reliable, standardized data to improve human health outcomes.